Document:

EXHIBIT
10.8

    

    HI-TECH
PHARMACAL CO., INC.

    369
BAYVIEW AVENUE

    AMITYVILLE,
NY 11701

    

    January 1, 2009

    

    Mr. Gary
April

    17 Alley
Pond Court

    Dix
Hills, NY  11746

    

    Dear Mr.
April:

    

    We are pleased to continue to secure
your employment upon the terms and conditions set forth in this
letter.

    

    Effective as of January 1, 2009 (the
“Effective Date”), you will continue to be employed by Hi-Tech Pharmacal Co.,
Inc. (the “Company”) as President of the Health Care Products Division (“HCP
Division”) for a term of twenty-four (24) months from the Effective Date, or
until terminated or extended as herein provided.  The Company will pay
to you as compensation for your services an annual salary in the amount of (i)
Two Hundred Twenty -Five Thousand ($225,000) Dollars for calendar year January
1, 2009 to December 31, 2009 (“Calendar 2009”); and (ii) Two Hundred Thirty-Five
Thousand ($235,000) Dollars for calendar year January 1, 2010 to December 31,
2010 (“Calendar 2010”).  Your salary shall be payable in weekly
installments less such deductions as shall be required to be withheld by
applicable law and regulations.  Prior to the end of each of Calendar
2009 and Calendar 2010, the Company’s Chief Executive Officer or Chief Financial
Officer will recommend to the Compensation Committee and Stock Option Committee
that you receive options to purchase seven thousand five hundred (7,500) shares
of the Company’s Common Stock; provided however, that the Compensation Committee
and Stock Option Committee shall make the final determination, in its
discretion, as to the number of options or other stock or equity based
compensation, if any, to be granted to you.

    

    In addition to your annual salary, you
will receive a bonus during each year of your employment equal to 2% of the
increase in Net Sales of the HCP Division over the immediately preceding year’s
Net Sales of the HCP Division (the “Bonus”).  For purposes of this
letter, the parties agree that (i) Domestic Sales for the period May 1, 2007 to
April 30, 2008 (“Fiscal 2008”) shall be deemed to be $10,846,000.  For
purposes of this letter, “Net Sales” shall mean gross sales net of any
deductions, returns, discounts, allowances, chargebacks and rebates, as
conclusively determined by the Company’s Chief Executive Officer or Chief
Financial Officer, which determination shall be final and binding upon you and
the Company.

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    While you are employed you may also
receive a profit bonus based on the Net Profits of the HCP
Division.  In the event the Net Profits of the HCP Division are
greater than the prior year’s Net Profits, then you will receive a profit bonus
(“Profit Bonus”) equal to 3% of the increase in Net Profits of the HCP Division
over the immediately preceding year’s Net Profits of the HCP
Division.  For purposes of this letter, the parties agree that Net
Profits for Fiscal 2008 shall be deemed to be $0.  The term “Net
Profits” as used herein shall mean the net profits of the HCP Division as
conclusively determined by the Company’s Chief Executive Officer or Chief
Financial Officer in accordance with the mutually agreed upon formula which is
attached hereto as Exhibit A.  Such determination by the Company’s
Chief Executive Officer or Chief Financial Officer shall be final and binding
upon you and the Company.

    

    While you are employed, you will be
entitled to a car allowance of $500 per month and you will be entitled to
participate in the Company’s pension, profit sharing, group insurance,
hospitalization and group health benefit plans and all other benefits and plans
as the Company provides to its senior executives.

    

    You will be entitled to a vacation of
four (4) weeks per year, during which time your salary will be paid in
full.  You will take your vacation at such times as you and the
Company shall determine is mutually convenient.

    

    In the event that during your
employment, all or substantially all of the assets or stock of the Company or of
the HCP Division of the Company are sold to a third party unrelated to any of
the current principal shareholders of the Company or its affiliates, you shall
be entitled to receive a “Sale Bonus”, payable, at the Company’s discretion, in
cash, stock options of the Company or other equity based
compensation.  The Sale Bonus shall be calculated in accordance with
the formula detailed on Exhibit B attached hereto.  Such Sale Bonus
shall be payable only in the event you are employed with the Company at the time
of the consummation of the sale.

    

    Your employment shall terminate in the
event you die, are totally disabled, wrongfully leave your employment, or your
employment is terminated pursuant to this letter agreement.

    

    In the event your employment is
terminated as a result of your death or total disability, if you are entitled to
a Bonus or a Profit Bonus, then you, your designee or your estate will be paid,
within thirty (30) days after the Company’s Chief Executive Officer or Chief
Financial Officer has determined the Net Sales and Net Profits of the Company’s
HCP Division, an amount equal to the product of (i) the sum of the Bonus and
Profit Bonus for such year in which death or total disability occurred and (ii)
a fraction, the numerator of which is the number of months during the year of
such death or total disability during which you were employed by the Company
through and including the month of your death or total disability, and the
denominator of which is twelve (12).

    

    For purposes of this letter, total
disability means that you are mentally or physically incapable or unable to
perform your regular and customary duties of employment with the Company for a
period of 90 consecutive or non-consecutive days in any 360 day
period.

    
      
         

      

      
        2

        
          

        

      

      
         

      

    

    The Company may terminate your
employment at any time “For Cause”.  For purposes of this letter, “For
Cause” shall include (i) your repeated failure to perform your duties, provided
that the Company shall have given you notice of your failure to perform your
duties and for a period of five (5) days thereafter, such failure shall not have
been remedied to the reasonable satisfaction of the Chief Executive Officer of
the Company; (ii) your inability to perform your duties at the level reasonably
expected of you by the Chief Executive Officer of the Company; (iii) your
willful refusal to follow, or reckless disregard of, the policies and directives
of the Chief Executive Officer of the Company; (iv) a material breach of your
responsibility to the Company; (v) misappropriation of the Company’s assets or
perpetration of fraud against, or dishonesty in dealings with the Company; or
(vi) your indictment for a crime which constitutes a felony.

    

    You may voluntarily terminate your
employment hereunder only upon the giving of six (6) months’ prior written
notice thereof to the Company (“Permissible Voluntary
Termination”).  In addition to your salary, in the event you are
entitled to a Bonus or a Profit Bonus, then you will be paid, within thirty (30)
days after the Company’s Chief Executive Officer or Chief Financial Officer has
determined the Net Profits of the Company’s HCP Division, an amount equal to the
product of (i) the sum of the Bonus and Profit Bonus for such year in which the
Permissible Voluntary Termination occurs and (ii) a fraction, the numerator of
which is the number of months during the year which you were employed by the
Company through and including the month of your Permissible Voluntary
Termination, and the denominator of which is twelve (12).  The date of
the Permissible Voluntary Termination shall be not less than six months after
your notice to the Company.

    

    In the event you leave your employment
without such prior notice or are discharged For Cause or you wrongfully leave
your employment, then, upon such occurrence, your employment shall be deemed
terminated and the Company shall be released from all obligations to you with
respect to this letter agreement except for your salary up to the date of such
termination.  You will not be entitled to any Bonus or Profit Bonus
for the year in which such termination occurs.

    

    By executing this letter, you
acknowledge receipt of, and agree to abide by, the Company’s Insider Trading
Policy.  Considering that the Company is a publicly-traded
corporation, you agree that you shall comply with any and all federal and state
securities laws, including but not limited to those that relate to
non-disclosure of information, insider trading and individual reporting
requirements and shall specifically abstain from discussing the non-public
aspects of the Company’s business affairs with any individual or group of
individuals (e.g., analysts, customers, Internet chat rooms) who does not have a
business need to know such information for the benefit of the
Company.  You further agree to immediately notify the Company’s
Compliance Officer in accordance with the Company’s Insider Trading Policy prior
to your acquisition or disposition of the Company’s securities.

    

    You recognize that the services to be
performed by you hereunder are special, unique and extraordinary.  The
parties confirm that it is reasonably necessary for the protection of the
Company that you agree, and, accordingly, you hereby agree, that during your
employment and for a period of twenty-four (24) months from and after the
termination of your employment (for any reason whatsoever) with the Company, you
shall not, directly or indirectly, within the United States:

    
      
         

      

      
        3

        
          

        

      

      
         

      

    

    

    
      	
               
      

            	
              ·

            	
              engage
      in a business which is competitive with the HCP Division (a “Competitive
      Business”) for your account or render any services that constitute
      engaging in a Competitive Business, in any capacity to any entity; or
      become interested or have an interest in any Competitive Business either
      on your own behalf or as an officer, director, stockholder, partner,
      principal, consultant, associate, employee, owner, agent, creditor,
      independent contractor, or co-venturer of any third party or in any other
      relationship or capacity; or

            

    

    

    
      	
               
      

            	
              ·

            	
              employ
      or engage, or cause to authorize, directly or indirectly, to be employed
      or engaged, for or on behalf of yourself or any third party, any employee,
      representative or agent of the Company;
or

            

    

    

    
      	
               
      

            	
              ·

            	
              solicit,
      directly or indirectly, on behalf of yourself or any third party, any
      customer, client or vendor of the Company and its
    affiliates.

            

    

    

    You acknowledge that as an employee of
the Company you will be exposed to the Company’s proprietary and confidential
information.  You agree that during or after your employment with the
Company (i) you shall not use such proprietary or confidential information for
any purposes whatsoever except in furtherance of the Company’s business and (ii)
you shall not disclose such proprietary or confidential information to any third
party, except at the direction of the Company.  You further agree that
upon the earlier of (i) the termination of your employment relationship with the
Company, or (ii) the Company’s request, you will deliver to the Company, or
destroy, all such confidential information in your possession or under your
control.

    

    If any of the restrictions contained in
this letter agreement shall be deemed to be unenforceable by reason of the
extent, duration or geographical scope thereof, or otherwise, then after such
restrictions have been reduced so as to be enforceable, in its reduced form this
letter agreement shall then be enforceable in the manner contemplated
hereby.

    

    The non-compete and confidentiality
provisions of this letter agreement shall survive the termination of your
employment hereunder.  You agree that any breach or threatened breach
by you of the non-compete and/or the confidentiality provisions of this letter
shall entitle the Company, in addition to all other legal remedies available to
it, to apply to any court of competent jurisdiction to enjoin such breach or
threatened breach.

    

    This letter sets forth the entire
agreement of the parties hereto and supersedes any prior agreements, promises,
covenants, arrangements, communications, representations or warranties, whether
oral or written with respect to the subject matter contained
herein.

    

    This letter, and the rights and
obligations herein, shall inure to the benefit of, be binding upon and
enforceable against, the parties hereto and their respective successors and
assigns.  This letter shall be governed by and construed in accordance
with the laws of the State of New York.

     

    
      
         

      

      
        4

        
          

        

      

      
         

      

    

    

    If the foregoing is acceptable to you,
please execute the enclosed copy of this letter in the space provided below and
return it to me at your earliest convenience.

    

    
      
        	 
      	
                Very
      truly yours,

              
	 
      	 
      
	 
      	
                Hi-Tech
      Pharmacal Co., Inc.

              
	 
      	 
      
	 
      	
                By:

              	
                /s/David S. Seltzer

              	 
      
	 
      	
                David
      S. Seltzer, President

              

      

    

    

    Accepted
and Agreed to this

    18th day
of February, 2009

    

    
      	
              /s/Gary M. April

            	 
      
	
              Gary
      M. April

            

    

    
      
         

      

      
        5

        
          

        

      

      
         

      

    

     

    EXHIBIT
A

    NET
PROFITS

    

    The term
“Net Profits” as used herein shall mean the “Net Sales” of the HCP Division less
the following expenses:

    
      	
               
      

            	
              (a)

            	
              Cost
      of Goods Sold;

            

    

    
      	
               
      

            	
              (b)

            	
              Direct
      costs of HCP (salaries, advertising, travel, regulatory, legal,
      etc.;

            

    

    
      	
               
      

            	
              (c)

            	
              Indirect
      costs allocated based on sales dollars (general, administrative, overhead
      and freight expenses);

            

    

    
      	
               
      

            	
              (d)

            	
              R&D
      expenses allocated on a project basis;
and

            

    

    
      	
               
      

            	
              (e)

            	
              Taxes,
      based on the corporate tax rate.

            

    

    

    For
purposes of this letter agreement:

    
      	
               
      

            	
              ·

            	
              “Net
      Sales” shall mean the gross sales of the HCP Division less all deductions,
      returns, discounts, allowances, chargebacks and
  rebates;

            

    

    
      	
               
      

            	
              ·

            	
              Indirect
      costs in accordance with subsection (c) above shall be deemed to equal 10%
      of Net Sales; and

            

    

    
      	
               
      

            	
              ·

            	
              The
      calculation of Net Profits shall be determined by the Company’s Chief
      Executive Officer or Chief Financial Officer, and such determination shall
      be final and binding upon the parties to this
  agreement.

            

    

     

    
      
         

      

      
        6

        
          

        

      

      
         

      

    

     

    EXHIBIT
B

    SALE
BONUS CALCULATION

    

    In the event of a sale of the Company,
then the Sale Bonus shall be equal to 2% of the Division Proceeds (as
hereinafter defined).

    

    In the event of a sale of the HCP
Division: (a) if the Net Sale Price (as hereinafter defined) is up to 1.5 times
the Sales of the HCP Division, then the Sale Bonus shall be equal to 2% of the
Division Proceeds; (b) if the Net Sale Price of the HCP Division is more than
1.5 times the Sales, but not more than 2 times the Sales of the HCP Division,
then the Sale Bonus shall be equal to 3% of the Division Proceeds; or (c) if the
Net Sale Price of the HCP Division is in excess of 2 times the Sales of the HCP
Division, then the Sale Bonus shall be equal to 4% of the Division
Proceeds.  For purposes of this paragraph only, Sales shall include
export sales.

    

    The term “Sales” shall mean the gross
sales of the HCP Division, net of any deductions, returns, discounts,
allowances, chargebacks and rebates.

    

    The term “Net Sale Price” shall mean
the actual net proceeds, less all direct and indirect expenses received by the
Company.  For purposes of this Exhibit, Sales shall be measured by the
fiscal year immediately preceding the sale of the HCP Division.

    

    The term “Division Proceeds” shall mean
(i) in the event of a sale of the HCP Division, the actual net proceeds, less
all direct and indirect expenses incurred by the Company for the HCP Division or
(ii) in the event of a sale of the Company, 1.5 times the Sales of the HCP
Division for the fiscal year immediately preceding the sale of the Company
(irrespective of the actual proceeds received by the Company).

    

    For illustration purposes, if for
Fiscal 2008 the Sales of the HCP Division were $8 million and the Sales of the
Company were $40 million and in 2008 the Company was sold for a Net Sale Price
of $80 million, then you would be entitled to 2% of the Division Proceeds for a
Sale Bonus of $240,000 (2% x ($8 million x 1.5)).  On the other hand,
if in 2008 the HCP Division was sold for a Net Sale Price of $16 million (2 x
Sales of the HCP Division), then you would be entitled to 3% of the Division
Proceeds for a Sale Bonus of $480,000 (3% x $16 million).

     

    In no event shall you be entitled to
more than one Sale Bonus.  The calculation of the Sale Bonus shall be
determined by the Company’s Chief Executive Officer or Chief Financial Officer,
and such determination shall be final and binding upon the parties to this
agreement.

    
      
         

      

      
        7SUBSCRIPTION
AGREEMENT

     

    THIS SUBSCRIPTION AGREEMENT
(this “Agreement”),
dated as of June __, 2009, by and among 3DIcon Corporation, an Oklahoma
corporation (the “Company”), and the subscribers
identified on the signature page hereto (each a “Subscriber” and collectively
“Subscribers”).

     

    WHEREAS, the Company and the
Subscribers are executing and delivering this Agreement in reliance upon an
exemption from securities registration afforded by the provisions of Section
4(2), Section 4(6) and/or Regulation D (“Regulation D”) as promulgated
by the United States Securities and Exchange Commission (the “Commission”) under the
Securities Act of 1933, as amended (the “1933 Act”).

     

    WHEREAS, the parties desire
that, upon the terms and subject to the conditions contained herein, the Company
shall issue and sell to the Subscribers, as provided herein, and the
Subscribers, in the aggregate, shall purchase for a minimum of $_______ (the
"Purchase Price") of
shares (the “Shares”) of
the Company's common stock, $.0002 par value (the "Common Stock") at a per share
price equal to 50% of the average of the average closing prices during the five
(5) days prior to June 15, 2009 as reported by Bloomberg, L.P, which is
$0.0068.

     

    NOW, THEREFORE, in
consideration of the mutual covenants and other agreements contained in this
Agreement the Company and the Subscribers hereby agree as follows:

     

    1.           Conditions To
Closing.   Subject to the satisfaction or waiver of the
terms and conditions of this Agreement, on the Closing Date, each Subscriber
shall purchase and the Company shall sell to each Subscriber the Shares
designated on the signature page hereto for the portion of the Purchase Price
set forth on the signature page hereto.  Each purchaser hereby
acknowledges that he or she may be the sole Subscriber.  On or before
the Closing Date, each Subscriber shall deliver to the Company such Subscriber’s
portion of the Purchase Price, an executed copy of this Agreement and a
completed Investor Questionnaire.  The payment will be delivered
pursuant to the following wire transfer instructions:

    

    
      	
            	
              Wire
      to: 

            	
               

            

    

     

    

    
      	
            	
              Acount
      Name: 

            	
               

            

    

    
      	
            	
              Account
      #: 

            	
               

            

    

    
      	
            	
              Routing
      #: 

            	
               

            

    

     

    2.           Closing.  The
consummation of the transactions contemplated herein shall take place upon the
satisfaction of all conditions to Closing set forth in this Agreement (“Closing Date”), provided,
however, that such Closing will occur on or before June __, 2009.

    

    3.           Reserved.

    

    4.           Subscriber's Representations
and Warranties.  Each Subscriber hereby represents and warrants
to and agrees with the Company only as to such Subscriber that:

    

    (a)           Organization and Standing of
the Subscribers.  If the
Subscriber is an entity, such Subscriber is a corporation, partnership or other
entity duly incorporated or organized, validly existing and in good standing
under the laws of the jurisdiction of its incorporation or organization and has
the requisite corporate power to own its assets and to carry on its
business.

     

    
      
        
        

      

      
        1

        
          

        

      

      
        
        

      

    

     

    (b)           Authorization and
Power.  Each Subscriber has the
requisite power and authority to enter into and perform this Agreement and to
purchase the Shares being sold to it hereunder.  The execution,
delivery and performance of this Agreement by such Subscriber and the
consummation by it of the transactions contemplated hereby and thereby have been
duly authorized by all necessary corporate or partnership action, and no further
consent or authorization of such Subscriber or its Board of Directors,
stockholders, partners, members, as the case may be, is
required.  This Agreement has been duly authorized, executed and
delivered by such Subscriber and constitutes, or shall constitute when executed
and delivered, a valid and binding obligation of the Subscriber enforceable
against the Subscriber in accordance with the terms thereof.

    

     (c)           No Conflicts.  The execution, delivery and performance of
this Agreement and the consummation by such Subscriber of the transactions
contemplated hereby or relating hereto do not and will not (i) result in a
violation of such Subscriber’s charter documents or bylaws or other
organizational documents or (ii) conflict with, or constitute a default (or an
event which with notice or lapse of time or both would become a default) under,
or give to others any rights of termination, amendment, acceleration or
cancellation of any agreement, indenture or instrument or obligation to which
such Subscriber is a party or by which its properties or assets are bound, or
result in a violation of any law, rule, or regulation, or any order, judgment or
decree of any court or governmental agency applicable to such Subscriber or its
properties (except for such conflicts, defaults and violations as would not,
individually or in the aggregate, have a material adverse effect on such
Subscriber).  Such Subscriber is not required to obtain any consent,
authorization or order of, or make any filing or registration with, any court or
governmental agency in order for it to execute, deliver or perform any of its
obligations under this Agreement or to purchase the Shares in accordance with
the terms hereof, provided that for purposes of the representation made in this
sentence, such Subscriber is assuming and relying upon the accuracy of the
relevant representations and agreements of the Company
herein.

     

    (d)           Information on
Company.   The Subscriber has been furnished with or has
had access at the EDGAR Website of the Commission to the Company's Form 10-K for
the year ended December 31, 2008 as filed with the SEC on April 15, 2009, the
Company’s Form 10-Q for the period ended March 31, 2009 as filed with the SEC on
May 20, 2009 and all periodic reports with the Commission thereafter, but not
later than five business days before the Closing Date (hereinafter referred to
as the "Reports").  In
addition, the Subscriber has received in writing from the Company such other
information concerning its operations, financial condition and other matters as
the Subscriber has requested in writing (such other information is collectively,
the "Other Written
Information"), and considered all factors the Subscriber deems material
in deciding on the advisability of investing in the Shares.

     

    (e)           Information on
Subscriber.  The Subscriber will be, on the Closing Date an
"accredited investor",
as such term is defined in Regulation D promulgated by the Commission under the
1933 Act, is experienced in investments and business matters, has made
investments of a speculative nature and has purchased securities of United
States publicly-owned companies in private placements in the past and, with its
representatives, has such knowledge and experience in financial, tax and other
business matters as to enable the Subscriber to utilize the information made
available by the Company to evaluate the merits and risks of and to make an
informed investment decision with respect to the proposed purchase, which
represents a speculative investment.  The Subscriber has the authority
and is duly and legally qualified to purchase and own the Shares.  The
Subscriber is able to bear the risk of such investment for an indefinite period
and to afford a complete loss thereof.  The information set forth on
the signature page hereto regarding the Subscriber is accurate.  The
Subscriber is not required to be registered as a broker-dealer under Section 15
of the Securities Exchange Act of 1934, as amended (the "1934 Act") and the
Subscriber is not a broker-dealer.

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

     

    (f) Investment
Purpose.  As of the date hereof, the Subscriber is purchasing
the Shares for its own account and not with a present view towards the public
sale or distribution thereof, except pursuant to sales registered or exempted
from registration under the 1933 Act; provided, however, that by
making the representations herein, the Subscriber does not agree to hold any of
the Shares for any minimum or other specific term and reserves the right to
dispose of the Shares at any time in accordance with or pursuant to a
registration statement or an exemption under the 1933 Act.

     

    (g) Reliance on
Exemptions.  The Subscriber understands that the Shares are
being offered and sold to it in reliance upon specific exemptions from the
registration requirements of United States federal and state securities laws and
that the Company is relying upon the truth and accuracy of, and the Subscriber’s
compliance with, the representations, warranties, agreements, acknowledgments
and understandings of the Subscriber set forth herein in order to determine the
availability of such exemptions and the eligibility of the Subscriber to acquire
the Shares.

     

     (h)           Purchase of
Shares.  On the Closing Date, the Subscriber will purchase the
Shares as principal for its own account for investment only and not with a view
toward, or for resale in connection with, the public sale or any distribution
thereof.

     

    (i)           Compliance with Securities
Act.   The Subscriber understands and agrees that the
Shares have not been registered under the 1933 Act or any applicable state
securities laws, by reason of their issuance in a transaction that does not
require registration under the 1933 Act (based in part on the accuracy of the
representations and warranties of Subscriber contained herein), and that such
Shares must be held indefinitely unless a subsequent disposition is registered
under the 1933 Act or any applicable state securities laws or is exempt from
such registration.  In any event, and subject to compliance with
applicable securities laws, the Subscriber may enter into lawful hedging
transactions with third parties, which may in turn engage in short sales of the
Shares in the course of hedging the position they assume and the Subscriber may
also enter into short positions or other derivative transactions relating to the
Shares, or interests in the Shares, and deliver the Shares, or interests in the
Shares, to close out their short or other positions or otherwise settle short
sales or other transactions, or loan or pledge the Shares, or interests in the
Shares, to third parties that in turn may dispose of these Shares.

     

     (j)           Shares
Legend.  The Shares shall bear the following or similar
legend:

     

    "THE
SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED.  THESE SHARES MAY NOT BE SOLD,
OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE
REGISTRATION STATEMENT UNDER SUCH SECURITIES ACT OR ANY APPLICABLE STATE
SECURITIES LAW OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO 3DICON
CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED."

     

     (l)           Communication of
Offer.  The offer to sell the Shares was directly communicated
to the Subscriber by the Company.  At no time was the Subscriber
presented with or solicited by any leaflet, newspaper or magazine article, radio
or television advertisement, or any other form of general advertising or
solicited or invited to attend a promotional meeting.

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

     

    (m)           Authority;
Enforceability.  This Agreement and other agreements delivered
together with this Agreement or in connection herewith have been duly
authorized, executed and delivered by the Subscriber and are valid and binding
agreements enforceable in accordance with their terms, subject to bankruptcy,
insolvency, fraudulent transfer, reorganization, moratorium and similar laws of
general applicability relating to or affecting creditors’ rights generally and
to general principles of equity; and Subscriber has full corporate power and
authority necessary to enter into this Agreement and such other agreements and
to perform its obligations hereunder and under all other agreements entered into
by the Subscriber relating hereto.

    

    (n)           Restricted
Shares.   Subscriber understands that the Shares have not
been registered under the 1933 Act and such Subscriber will not sell, offer to
sell, assign, pledge, hypothecate or otherwise transfer any of the Shares unless
pursuant to an effective registration statement under the 1933
Act.  Notwithstanding anything to the contrary contained in this
Agreement, such Subscriber may transfer (without restriction and without the
need for an opinion of counsel) the Shares to its Affiliates (as defined below)
provided that each such Affiliate is an “accredited investor” under Regulation D
and such Affiliate agrees to be bound by the terms and conditions of this
Agreement. For the purposes of this Agreement, an “Affiliate” of any person or
entity means any other person or entity directly or indirectly controlling,
controlled by or under direct or indirect common control with such person or
entity.  For purposes of this definition, “control” means the power to
direct the management and policies of such person or firm, directly or
indirectly, whether through the ownership of voting securities, by contract or
otherwise.

    

    (o)           No Governmental
Review.  Each Subscriber understands that no United States
federal or state agency or any other governmental or state agency has passed on
or made recommendations or endorsement of the Shares or the suitability of the
investment in the Shares nor have such authorities passed upon or endorsed the
merits of the offering of the Shares.

    

     (p)           Correctness of
Representations.  Each Subscriber represents as to such
Subscriber that the foregoing representations and warranties are true and
correct as of the date hereof and, unless a Subscriber otherwise notifies the
Company prior to the Closing Date shall be true and correct as of the Closing
Date.

    

    (q)           Survival.   The
foregoing representations and warranties shall survive the Closing Date for a
period of three years.

     

    5.           Company Representations and
Warranties.  The Company represents and warrants to and agrees
with each Subscriber that:

     

    (a)           Due
Incorporation.  The Company is a corporation or other entity
duly incorporated or organized, validly existing and in good standing under the
laws of the jurisdiction of its incorporation or organization and has the
requisite corporate power to own its properties and to carry on its business as
presently conducted.  The Company is duly qualified as a foreign
corporation to do business and is in good standing in each jurisdiction where
the nature of the business conducted or property owned by it makes such
qualification necessary, other than those jurisdictions in which the failure to
so qualify would not have a Material Adverse Effect.  For purposes of
this Agreement, a “Material
Adverse Effect” shall mean a material adverse effect on the financial
condition, results of operations, properties or business of the Company and its
Subsidiaries taken as a whole.

     

    (b)           Outstanding
Stock.  All issued and outstanding shares of capital stock of
the Company has been duly authorized and validly issued and are fully paid and
nonassessable.

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

     

    (c)           Authority;
Enforceability.  This Agreement,  the Shares, and any
other agreements delivered together with this Agreement or in connection
herewith (collectively “Transaction Documents”) have
been duly authorized, executed and delivered by the Company and are valid and
binding agreements enforceable in accordance with their terms, subject to
bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and
similar laws of general applicability relating to or affecting creditors' rights
generally and to general principles of equity.  The Company has full
corporate power and authority necessary to enter into and deliver the
Transaction Documents and to perform its obligations thereunder.

     

     (d)           Consents.  No
consent, approval, authorization or order of any court, governmental agency or
body or arbitrator having jurisdiction over the Company, or any of its
Affiliates, the OTC Bulletin Board nor the Company's shareholders is required
for the execution by the Company of the Transaction Documents and compliance and
performance by the Company of its obligations under the Transaction Documents,
including, without limitation, the issuance and sale of the Shares.

     

     (e)           The
Shares.  The Shares upon issuance:

     

    (i)           are,
or will be, free and clear of any security interests, liens, claims or other
encumbrances, subject to restrictions upon transfer under the 1933 Act and any
applicable state securities laws;

    

    (ii)           have
been, or will be, duly and validly authorized and on the date of issuance of the
Shares will be duly and validly issued, fully paid and nonassessable or if
registered pursuant to the 1933 Act, and resold pursuant to an effective
registration statement will be free trading and unrestricted;

     

    (iii)           will
not have been issued or sold in violation of any preemptive or other similar
rights of the holders of any securities of the Company;

     

    (iv)           will
not subject the holders thereof to personal liability by reason of being such
holders; and

     

    (v)           will
not result in a violation of Section 5 under the Act.

     

    (f)           Litigation.  There
is no pending or, to the best knowledge of the Company, threatened action, suit,
proceeding or investigation before any court, governmental agency or body, or
arbitrator having jurisdiction over the Company, or any of its Affiliates that
would affect the execution by the Company or the performance by the Company of
its obligations under the Transaction Documents.  Except as disclosed
in the Reports, there is no pending or, to the best knowledge of the Company,
basis for or threatened action, suit, proceeding or investigation before any
court, governmental agency or body, or arbitrator having jurisdiction over the
Company, or any of its Affiliates which litigation if adversely determined would
have a Material Adverse Effect.

     

     (g)           No Market
Manipulation.  The Company and its Affiliates have not taken,
and will not take, directly or indirectly, any action designed to, or that might
reasonably be expected to, cause or result in stabilization or manipulation of
the price of the Common Stock to facilitate the sale or resale of the Shares or
affect the price at which the Shares may be issued or resold.

     

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

     

    (h)           Information Concerning
Company.     Since the date of the financial
statements included in the Reports (“Latest Financial Date”), and
except as modified in the Other Written Information, there has been no Material
Adverse Event relating to the Company's business, financial condition or affairs
not disclosed in the Reports. The Reports, including the financial statements
contained therein, do not contain any untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary to make
the statements therein not misleading in light of the circumstances when
made.

     

    (i)           Stop
Transfer.  The Company will not issue any stop transfer order
or other order impeding the sale, resale or delivery of any of the Shares,
except as may be required by any applicable federal or state securities laws and
unless contemporaneous notice of such instruction is given to the
Subscriber.

     

    (j)           Defaults.   The
Company is not in violation of its articles of incorporation or
bylaws.  The Company is (i) not in default with respect to any order
of any court, arbitrator or governmental body or subject to or party to any
order of any court or governmental authority arising out of any action, suit or
proceeding under any statute or other law respecting antitrust, monopoly,
restraint of trade, unfair competition or similar matters, or (ii) to the
Company’s knowledge not in violation of any statute, rule or regulation of any
governmental authority which violation would have a Material Adverse
Effect.

     

    (k)           Not Integrated
Offering. Neither the Company, nor any of its Affiliates, nor any
person acting on its or their behalf, has directly or indirectly made any offers
or sales of any security or solicited any offers to buy any security under
circumstances that would cause the offer of the Shares pursuant to this
Agreement to be integrated with prior offerings by the Company for purposes of
the 1933 Act or any applicable stockholder approval provisions, including,
without limitation, under the rules and regulations of the OTC Bulletin Board
(“Bulletin Board”) or
any Principal Market [as defined in Section 9(b)] which would impair the
exemptions relied upon in this Offering or the Company’s ability to timely
comply with its obligations hereunder.  Nor will the Company or any of
its Affiliates take any action or steps that would cause the offer or issuance
of the Shares to be integrated with other offerings which would impair the
exemptions relied upon in this Offering or the Company’s ability to timely
comply with its obligations hereunder.  The Company will not conduct
any offering other than the transactions contemplated hereby that will be
integrated with the offer or issuance of the Shares, which would impair the
exemptions relied upon in this Offering or the Company’s ability to timely
comply with its obligations hereunder.

     

    (l)           No General
Solicitation.  Neither the Company, nor any of its Affiliates,
nor to its knowledge, any person acting on its or their behalf, has engaged in
any form of general solicitation or general advertising (within the meaning of
Regulation D under the 1933 Act) in connection with the offer or sale of the
Shares.

     

    (m)           Listing.  The
Common Stock is quoted on the Bulletin Board under the symbol: TDCP.OB. The
Company has not received any oral or written notice that the Common Stock is not
eligible nor will become ineligible for quotation on the Bulletin Board nor that
the Common Stock does not meet all requirements for the continuation of such
quotation and the Company satisfies all the requirements for the continued
quotation of the Common Stock on the Bulletin Board.

     

    (n)           No Undisclosed
Liabilities.  The Company has no liabilities or obligations
which are material, individually or in the aggregate, which are not disclosed in
the Reports and Other Written Information, other than those incurred in the
ordinary course of the Company’s businesses since the Latest Financial Date and
which, individually or in the aggregate, would reasonably be expected to have a
Material Adverse Effect.

     

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

     

    (o)           No Undisclosed Events or
Circumstances.  Since the Latest Financial Date, no event or
circumstance has occurred or exists with respect to the Company or its
businesses, properties, operations or financial condition, that, under
applicable law, rule or regulation, requires public disclosure or announcement
prior to the date hereof by the Company but which has not been so publicly
announced or disclosed in the Reports.

     

    (p)           Capitalization.  The
authorized and outstanding capital stock of the Company as of the date of this
Agreement and the Closing Date (not including the Shares) are set forth on Schedule
5(d).  Except as set forth on Schedule 5(d), there are no
options, warrants, or rights to subscribe to, securities, rights or obligations
convertible into or exchangeable for or giving any right to subscribe for any
shares of capital stock of the Company or any of its
Subsidiaries.  All of the outstanding shares of Common Stock of the
Company have been duly and validly authorized and issued and are fully paid and
nonassessable.

     

    (q)           Dilution.   The
Company's executive officers and directors understand the nature of the Shares
being sold hereby and recognize that the issuance of the Shares will have a
potential dilutive effect on the equity holdings of other holders of the
Company’s equity or rights to receive equity of the Company.  The
board of directors of the Company has concluded, in its good faith business
judgment that the issuance of the Shares is in the best interests of the
Company.  (r)No Disagreements with
Accountants and Lawyers.  There are no disagreements of any
kind presently existing, or reasonably anticipated by the Company to arise,
between the Company and the accountants and lawyers formerly or presently
employed by the Company, including but not limited to disputes or conflicts over
payment owed to such accountants and lawyers, nor have there been any such
agreements during the two years prior to the Closing Date.

    

    (s)           DTC
Status.   The Company’s transfer agent is a participant in
and the Common Stock is eligible for transfer pursuant to the Depository Trust
Company Automated Securities Transfer Program.  The name, address,
telephone number, fax number, contact person and email address of the Company
transfer agent is set forth on Schedule 5(s) hereto.

    

    (t)           Investment
Company.   Neither the Company nor any Affiliate is an
“investment company” within the meaning of the Investment Company Act of 1940,
as amended.

    

    (u)           Reserved.

    

    (v)           Company
Predecessor.   All representations made by or relating to
the Company of a historical or prospective nature and all undertaking described
in Section 5 shall relate and refer to the Company and its
predecessors.

    

    (w)           Correctness of
Representations.  The Company represents that the foregoing
representations and warranties are true and correct as of the date hereof in all
material respects, and, unless the Company otherwise notifies the Subscribers
prior to the Closing Date, shall be true and correct in all material respects as
of the Closing Date.

     

    (x)           Survival.  The
foregoing representations and warranties shall survive the Closing Date for a
period of three years.

     

    6.           Regulation D
Offering.  The offer and issuance of the Shares to the
Subscribers is being made pursuant to the exemption from the registration
provisions of the 1933 Act afforded by Section 4(2) or Section 4(6) of the 1933
Act and/or Rule 506 of Regulation D promulgated thereunder  The
Company will provide, at the Company's expense, such other legal opinions in the
future as are reasonably necessary for the issuance and/or resale of the Shares
pursuant to an effective registration statement, Rule 144 under the 1933 Act, or
an exemption from registration.

     

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

     

    7.           Reserved.

     

    8.           Reserved

     

    9.           Covenants of the
Company.  The Company covenants and agrees with the Subscribers
as follows:

     

    (a)           Stop
Orders.  The Company will advise the Subscribers within two
hours after it receives notice of issuance by the SEC, any state securities
commission or any other regulatory authority of any stop order or of any order
preventing or suspending any offering of any securities of the Company, or of
the suspension of the qualification of the Common Stock of the Company for
offering or sale in any jurisdiction, or the initiation of any proceeding for
any such purpose.

     

    (b)           Principal
Market.  The Company will maintain the quotation of its Common
Stock on the Bulletin Board (the “Principal Market”)), and will
comply in all respects with the Company's reporting, filing and other
obligations under the bylaws or rules of the Principal Market, as applicable.
The Company will provide the Subscribers copies of all notices it receives
notifying the Company of the threatened and actual delisting of the Common Stock
from any Principal Market.  As of the date of this Agreement and the
Closing Date, the Bulletin Board is and will be the Principal
Market.

     

    (c)           Market
Regulations.  The Company shall notify the SEC, the Principal
Market and applicable state authorities, in accordance with their requirements,
of the transactions contemplated by this Agreement, and shall take all other
necessary action and proceedings as may be required and permitted by applicable
law, rule and regulation, for the legal and valid issuance of the Securities to
the Subscribers and promptly provide copies thereof to Subscriber.

     

    (d)           Filing
Requirements.  From the date of this Agreement and until the
sooner of (i) three (3) years after the Closing Date, or (ii) until all the
Shares have been resold or transferred by all the Subscribers pursuant to the
Registration Statement or pursuant to Rule 144, the Company will (A) cause its
Common Stock to continue to be subject to the reporting obligations of Section
15(d), 12(b) or 12(g) of the 1934 Act, (B) comply in all respects with its
reporting and filing obligations under the 1934 Act, (C) comply with all
reporting requirements that are applicable to an issuer subject to Section 15(d)
of the 1934 Act, or, if a class of its securities is registered under Section
12(b) or 12(g) of the 1934 Act, to all reporting requirements that are
applicable to an issuer with a class of shares registered pursuant to Section
12(b) or 12(g) of the 1934 Act, as applicable, and (D) comply with all
requirements related to any registration statement filed pursuant to this
Agreement.  The Company will use its best efforts not to take any
action or file any document (whether or not permitted by the 1933 Act or the
1934 Act or the rules thereunder) to terminate or suspend such registration or
to terminate or suspend its reporting and filing obligations under said acts or
until three (3) years after the Closing Date.  Until the he resale of
the Shares by each Subscriber, the Company will use its best efforts to continue
the listing or quotation of the Common Stock on the Principal Market and will
comply in all respects with the Company's reporting, filing and other
obligations under the bylaws or rules of the Principal Market.  The
Company agrees to timely file a Form D with respect to the Securities if
required under Regulation D and to provide a copy thereof to each Subscriber
promptly after such filing.

     

    (e)           Use of
Proceeds.  The proceeds of the Offering will be employed by the
Company for general working capital purposes.

    
      
         

      

      
        8

        
          

        

      

      
         

      

    

     

    (f)           Reserved.

     

    (g)           Non-Public
Information.  The Company covenants and agrees that neither it
nor any other person acting on its behalf will provide any Subscriber or its
agents or counsel with any information that the Company believes constitutes
material non-public information, unless prior thereto such Subscriber shall have
agreed in writing to receive such information.  The Company
understands and confirms that each Subscriber shall be relying on the foregoing
representations in effecting transactions in securities of the Company. 10.
Covenants of the
Company and Subscriber Regarding Indemnification.

     

    (a)           The
Company agrees to indemnify, hold harmless, reimburse and defend the
Subscribers, the Subscribers' officers, directors, agents, Affiliates, control
persons, and principal shareholders, against any claim, cost, expense,
liability, obligation, loss or damage (including reasonable legal fees) of any
nature, incurred by or imposed upon the Subscriber or any such person which
results, arises out of or is based upon (i) any material misrepresentation by
Company or breach of any warranty by Company in this Agreement or in any
Exhibits or Schedules attached hereto, or other agreement delivered pursuant
hereto; or (ii) after any applicable notice and/or cure periods, any breach or
default in performance by the Company of any material covenant or undertaking to
be performed by the Company hereunder, or any other agreement entered into by
the Company and Subscriber relating hereto. Any or all of the foregoing are
deemed Events of Default.

     

    (b)           Each
Subscriber agrees to indemnify, hold harmless, reimburse and defend the Company
and each of the Company’s officers, directors, agents, Affiliates, control
persons against any claim, cost, expense, liability, obligation, loss or damage
(including reasonable legal fees) of any nature, incurred by or imposed upon the
Company or any such person which results, arises out of or is based upon (i) any
material misrepresentation by such Subscriber in this Agreement or in any
Exhibits or Schedules attached hereto, or other agreement delivered pursuant
hereto; or (ii) after any applicable notice and/or cure periods, any breach or
default in performance by such Subscriber of any covenant or undertaking to be
performed by such Subscriber hereunder, or any other agreement entered into by
the Company and Subscribers, relating hereto.

     

    (c)           In
no event shall the liability of any Subscriber or permitted successor hereunder
or under any Transaction Document or other agreement delivered in connection
herewith be greater in amount than the dollar amount of the net proceeds
actually received by such Subscriber upon the sale of Registrable Securities (as
defined herein).

    

    11.           Reserved.

     

    12.           Reserved.

    
      
         

      

      
        9

        
          

        

      

      
         

      

    

     

    13.           Miscellaneous.

    

    (a)           Notices.  All
notices, demands, requests, consents, approvals, and other communications
required or permitted hereunder shall be in writing and, unless otherwise
specified herein, shall be (i) personally served, (ii) deposited in the mail,
registered or certified, return receipt requested, postage prepaid, (iii)
delivered by reputable air courier service with charges prepaid, or (iv)
transmitted by hand delivery, telegram, or facsimile, addressed as set forth
below or to such other address as such party shall have specified most recently
by written notice.  Any notice or other communication required or
permitted to be given hereunder shall be deemed effective (a) upon hand delivery
or delivery by facsimile, with accurate confirmation generated by the
transmitting facsimile machine, at the address or number designated below (if
delivered on a business day during normal business hours where such notice is to
be received), or the first business day following such delivery (if delivered
other than on a business day during normal business hours where such notice is
to be received) or (b) on the second business day following the date of mailing
by express courier service, fully prepaid, addressed to such address, or upon
actual receipt of such mailing, whichever shall first occur.  The
addresses for such communications shall be: (i) if to the Company, to: 3DIcon
Corporation, 6804 South Canton Avenue, Suite 150, Tulsa, OK, 74136, Attn: Martin
Keating, Chief Executive Officer, telecopier: (918) 492-5367, with a copy by
telecopier only to: Sichenzia Ross Friedman Ference LLP, 61 Broadway, New York,
NY 10006, Attn: Sean F. Reid, Esq., telecopier: (212) 930-9725, (ii) if to the
Subscribers, to: the one or more addresses and telecopier numbers indicated on
the signature pages hereto.

     

    (b)           Nothing
contained herein or in any document referred to herein or delivered in
connection herewith shall be deemed to establish or require the payment of a
rate of interest or other charges in excess of the maximum permitted by
applicable law.  In the event that the rate of interest or dividends
required to be paid or other charges hereunder exceed the maximum permitted by
such law, any payments in excess of such maximum shall be credited against
amounts owed by the Company to the Subscriber and thus refunded to the
Company.

     

    (c)           Entire Agreement;
Assignment.  This Agreement and other documents delivered in
connection herewith represent the entire agreement between the parties hereto
with respect to the subject matter hereof and may be amended only by a writing
executed by both parties.  Neither the Company nor the Subscribers
have relied on any representations not contained or referred to in this
Agreement and the documents delivered herewith.   No right or
obligation of the Company shall be assigned without prior notice to and the
written consent of the Subscribers.

     

    (d)           
Counterparts/Execution.  This Agreement may be executed in any
number of counterparts and by the different signatories hereto on separate
counterparts, each of which, when so executed, shall be deemed an original, but
all such counterparts shall constitute but one and the same
instrument.  This Agreement may be executed by facsimile signature and
delivered by facsimile transmission.

     

    (e)           Law Governing this
Agreement.  This Agreement shall be governed by and construed
in accordance with the laws of the State of New York without regard to conflicts
of laws principles that would result
in the application of the substantive laws of another
jurisdiction.  Any action brought by either party against the other
concerning the transactions contemplated by this Agreement shall be brought only
in the state courts of New York or in the federal courts located in the state of
New York.  The
parties and the individuals executing this Agreement and other agreements
referred to herein or delivered in connection herewith on behalf of the Company
agree to submit to the jurisdiction of such courts and waive trial by
jury.  The prevailing party shall be entitled to recover from
the other party its reasonable attorney's fees and costs.  In the
event that any provision of this Agreement or any other agreement delivered in
connection herewith is invalid or unenforceable under any applicable statute or
rule of law, then such provision shall be deemed inoperative to the extent that
it may conflict therewith and shall be deemed modified to conform with such
statute or rule of law.  Any such provision which may prove invalid or
unenforceable under any law shall not affect the validity or enforceability of
any other provision of any agreement.

    
      
         

      

      
        10

        
          

        

      

      
         

      

    

     

    (f)           Specific Enforcement,
Consent to Jurisdiction.  The Company and Subscriber
acknowledge and agree that irreparable damage would occur in the event that any
of the provisions of this Agreement were not performed in accordance with their
specific terms or were otherwise breached.  It is accordingly agreed
that the parties shall be entitled to one or more preliminary and final
injunctions to prevent or cure breaches of the provisions of this Agreement and
to enforce specifically the terms and provisions hereof, this being in addition
to any other remedy to which any of them may be entitled by law or
equity.  Subject to Section 13(e) hereof, each of the Company,
Subscriber and any signator hereto in his personal capacity hereby waives, and
agrees not to assert in any such suit, action or proceeding, any claim that it
is not personally subject to the jurisdiction in New York of such court, that
the suit, action or proceeding is brought in an inconvenient forum or that the
venue of the suit, action or proceeding is improper.  Nothing in this
Section shall affect or limit any right to serve process in any other manner
permitted by law.

     

    (g)           Independent Nature of
Subscribers.     The Company acknowledges that the
obligations of each Subscriber under the Transaction Documents are several and
not joint with the obligations of any other Subscriber, and no Subscriber shall
be responsible in any way for the performance of the obligations of any other
Subscriber under the Transaction Documents. The Company acknowledges that each
Subscriber has represented that the decision of each Subscriber to purchase
Securities has been made by such Subscriber independently of any other
Subscriber and independently of any information, materials, statements or
opinions as to the business, affairs, operations, assets, properties,
liabilities, results of operations, condition (financial or otherwise) or
prospects of the Company which may have been made or given by any other
Subscriber or by any agent or employee of any other Subscriber, and no
Subscriber or any of its agents or employees shall have any liability to any
Subscriber (or any other person) relating to or arising from any such
information, materials, statements or opinions.  The Company acknowledges
that nothing contained in any Transaction Document, and no action taken by any
Subscriber pursuant hereto or thereto shall be deemed to constitute the
Subscribers as a partnership, an association, a joint venture or any other kind
of entity, or create a presumption that the Subscribers are in any way acting in
concert or as a group with respect to such obligations or the transactions
contemplated by the Transaction Documents.  The Company acknowledges that
each Subscriber shall be entitled to independently protect and enforce its
rights, including without limitation, the rights arising out
of the Transaction Documents, and it shall not be necessary for any
other Subscriber to be joined as an additional party in any proceeding for such
purpose.  The Company acknowledges that it has elected to provide all
Subscribers with the same terms and Transaction Documents for the convenience of
the Company and not because Company was required or requested to do so by the
Subscribers.  The Company acknowledges that such procedure with respect to
the Transaction Documents in no way creates a presumption that the Subscribers
are in any way acting in concert or as a group with respect to the Transaction
Documents or the transactions contemplated thereby.

     

    (f)           Damages.   In
the event the Subscriber is entitled to receive any liquidated damages pursuant
to the Transactions, the Subscriber may elect to receive the greater of actual
damages or such liquidated damages.

     

    (g)           Consent.   As
used in the Agreement and except as otherwise specifically stated, “consent of
the Subscribers” or similar language means the consent of holders of not less
than 50.1% of the total of the Shares issued owned by Subscribers on the date
consent is requested.

     

    (h)           Equal
Treatment.   No consideration shall be offered or paid to
any person to amend or consent to a waiver or modification of any provision of
the Transaction Documents unless the same consideration is also offered and paid
to all the Subscribers and their permitted successors and assigns.

    

    [THIS
SPACE INTENTIONALLY LEFT BLANK]

    
      
         

      

      
        11

        
          

        

      

      
         

      

    

     

    SIGNATURE PAGE TO
SUBSCRIPTION AGREEMENT

    

    Please
acknowledge your acceptance of the foregoing Subscription Agreement by signing
and returning a copy to the undersigned whereupon it shall become a binding
agreement between us.

    

    
      
        
          
            	
                    3DIcon
      Corporation

                  
	
                    an
      Oklahoma corporation

                  
	 
      
	
                    By:

                  	 
      
	
                    Name:

                  	
                    Martin
      Keating

                  
	
                    Title:

                  	
                    CEO

                  
	 
      
	
                    Dated:
      June ___, 2009

                  

          

        

      

    

    

    
      
        
          
            
              
                
                  
                    	
                            SUBSCRIBER

                          	 	
                            PURCHASE

                            PRICE

                          	 	
                            SHARES OF

                            COMMON

                            STOCK

                          
	
                            Name
      of Subscriber:

                             

                            ________________________________

                            Tax
      ID / SS#:

                             

                            _______________________________

                             

                            Address:
      

                            ________________________________

                             

                            ________________________________

                             

                            Fax
      No.:

                            ________________________________

                             

                             

                            ________________________________

                            (Signature)

                            By:

                          	 	 
      	 	 
      

                  

                

              

            

          

        

      

    

    
      
         

      

      
        
        

        
          

        

      

      
         

      

    

    LIST OF
SCHEDULES

     

    Schedule
5(d)                          Additional
Issuances / Capitalization

     

    Schedule
5(s)                           Transfer
Agent

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00160-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00160-of-00352.parquet"}]]